0001636050-22-000020.txt : 20220210
0001636050-22-000020.hdr.sgml : 20220210
20220210170527
ACCESSION NUMBER: 0001636050-22-000020
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220208
FILED AS OF DATE: 20220210
DATE AS OF CHANGE: 20220210
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Nassif David W.
CENTRAL INDEX KEY: 0001636975
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 22615137
MAIL ADDRESS:
STREET 1: C/O STEADYMED THERAPEUTICS, INC.
STREET 2: 2410 CAMINO RAMON
CITY: SAN RAMON
STATE: CA
ZIP: 94583
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Sio Gene Therapies Inc.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 853863315
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 130 WEST 42ND STREET
STREET 2: 26TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
BUSINESS PHONE: 877-746-4891
MAIL ADDRESS:
STREET 1: 130 WEST 42ND STREET
STREET 2: 26TH FLOOR
CITY: NEW YORK
STATE: NY
ZIP: 10036
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Gene Therapies Ltd.
DATE OF NAME CHANGE: 20190516
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences Ltd.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
4
1
wf-form4_164453070649941.xml
FORM 4
X0306
4
2022-02-08
0
0001636050
Sio Gene Therapies Inc.
SIOX
0001636975
Nassif David W.
C/O SIO GENE THERAPIES INC.
130 WEST 42ND STREET, 26TH FLOOR
NEW YORK
NY
10036
1
1
0
0
Interim CEO, CFO
Restricted Stock Units
2022-02-08
4
A
0
546500
0
A
Common Stock
546500.0
546500
D
Each restricted stock unit represents the right to receive one share of the Issuer's common stock.
One-third of the restricted stock units shall vest on February 8, 2023, February 8, 2024 and February 8, 2025, subject to the Reporting Person providing continuous service to the Issuer through each such date.
/s/ David Nassif
2022-02-10